August 2017

Science Exchange signs on as LabCentral sponsor

Wednesday, August 30, 2017

Biotech innovation hub LabCentral has signed Science Exchange, a secure platform for outsourced research and development (R&D), as a sponsor to support its life science and biotech resident startups. Companies within LabCentral’s shared workspaces are now able to order R&D services instantly via a customized Science Exchanged-powered marketplace, with access to more than 2,500 qualified scientific service providers.

[Read More]

LifeArc, AUTM partner on training for scholars in technology transfer

Wednesday, August 30, 2017

LifeArc, the medical research charity formerly known as MRC Technology, has partnered with The Association of University Technology Managers (AUTM) Foundation to offer a competitive program that will provide essential training for scientists seeking a career in life sciences technology transfer. This joint initiative emphasizes the commitment of both organizations to improve access to the technology transfer profession.

[Read More]

Parcom Capital acquires Viroclinics Biosciences

Wednesday, August 30, 2017

Viroclinics, founded in 2001 and specializing in testing new vaccines and drugs in the clinical trial stages prior to their market launch, has been acquired by Parcom Capital. Viroclinics has clients across the globe and conducts virology testing for clients that include the world’s top 10 biopharmaceutical companies. The company is also a market leader in the Netherlands. For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.

[Read More]

NIH’s All of Us Research Program expands medical centers network

Wednesday, August 30, 2017

Three sets of healthcare provider organizations will add to a growing network of trusted leaders charged with implementing the NIH’s All of Us Research Program, an ambitious effort to advance research into precision medicine. Combined, the new awardees will receive $13.8 million to enroll interested individuals, gather participant health information and help retain participants in the program through ongoing engagement efforts. These awardees will extend the geographic coverage of the program and strengthen its reach within underserved communities, including lower-income, Hispanic and Latino, African American, American Indian and rural communities.

[Read More]

Abeona receives FDA breakthrough designation for epidermolysis bullosa

Wednesday, August 30, 2017

Abeona Therapeutics, a clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced that the FDA has granted Breakthrough Therapy designation status to the company’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB). The designation from the FDA enables collaborative discussions with senior FDA personnel, priority review and an expedited approval process to drug candidates where preliminary clinical trials indicate that a therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases.

[Read More]

LabCorp names Dr. Brian Caveney as enterprise-wide chief medical officer

Tuesday, August 29, 2017

LabCorp, a global life sciences company, announced that Dr. Brian Caveney, a nationally recognized health-policy expert who currently serves as chief medical officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC), will fill a newly created role as enterprise-wide chief medical officer of LabCorp, effective Sept. 25. Caveney will report to David P. King, chairman and CEO of LabCorp.

[Read More]

FDA grants Priority Review for Genentech’s Gazyva

Tuesday, August 29, 2017

Genentech, a member of the Roche Group, announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Gazyva (obinutuzumab) in combination with chemotherapy followed by Gazyva alone for people with previously untreated follicular lymphoma, one of the most common blood cancers among adults. Follicular lymphoma, a slow-growing (indolent) form of non-Hodgkin’s lymphoma, is incurable and characterized by cycles of remission and relapse.

[Read More]

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Tuesday, August 29, 2017

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.

[Read More]